Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that cancer cells switch to brute force and build a protrusion when MMP enzymes aren't available. This allows them to penetrate the basement membrane and invade other organs. The study identified a mitochondrial gene target that could be used to develop new treatments.
Shapiro's comprehensive program in early cancer drug development has provided scientific and clinical direction for multiple investigational agents. His work has contributed to the advancement of several approved drugs, including CDK4/6 inhibitors.
A new test for pediatric tumour analysis has been developed that may provide faster diagnosis times and more accurate genetic mutation detection. The test uses DNA sequencing technology to identify weaknesses in tumor cells that can be targeted with drugs, offering potential improvements in treatment options for children with cancer.
Researchers have discovered a promising new drug that targets the biological clock of cancer cells, slowing their growth and halting their spread. By disrupting the circadian rhythm of cancer cells, this drug may provide an effective new treatment option for various types of cancer.
Finasteride has been shown to reduce the risk of prostate cancer by 25 percent, with no significant increase in mortality rates. The study's findings have eliminated concerns over initial reports of potential risks, and doctors are now recommending finasteride as a preventive strategy for prostate cancer.
Researchers at University College London have discovered the genetic differences between lung cancer precursor cells and harmless lesions. This breakthrough could lead to the development of screening tests and new treatments that can stop cancer in its tracks, saving lives by detecting the disease earlier.
Researchers at University at Buffalo received an $880,000 grant to develop a model of the female reproductive tract for testing drugs delivered vaginally or to the uterus. This project aims to create cost-effective generic equivalents for existing medications, addressing the limited availability of affordable treatment options.
Researchers uncover potent and selective inhibitor of SHP2, a key target for cancer treatment. The discovery could lead to improved cancer drugs and new strategies for killing cancer cells.
SYNB1020, Synlogic's Synthetic Biotic medicine, demonstrates safety and proof of mechanism in healthy volunteers, clearing ammonia from the blood. The therapy is being evaluated in patients with cirrhosis and elevated blood ammonia, offering a potential new treatment for hyperammonemia.
Researchers at Columbia University have developed a chemical process to convert infrared light to visible energy, allowing innocuous radiation to penetrate living tissue without damaging it. This technology holds promise for enhancing the effectiveness of photodynamic therapy in treating various diseases.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
Researchers develop a novel approach to target aggressive liver cancer by inhibiting protein production, leaving healthy cells unharmed. The study shows promising results using a genetic approach and a drug that directly inhibits translation, slowing tumor growth and blocking immune evasion.
A landmark study published in the New England Journal of Medicine has found that ibrutinib is significantly more effective than standard therapy in treating CLL, causing fewer side effects and requiring less frequent patient visits. Ibrutinib was shown to improve survival rates by 13% compared to standard treatment.
A team of researchers at the University of Zurich has determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy. They found that effective drugs like EmendTM and AkynzeoTM alter the receptor's structure, allowing for long-lasting attachment and effective treatment.
Researchers at Emory University have developed a high-throughput screening platform to identify small molecules that can enhance the ability of human immune cells to kill cancer cells. The platform, called HTiP, has identified compounds such as birinapant, which has shown strong evidence for its relevance as an immune enhancer.
Researchers have developed a 'drug sponge' that can absorb up to 64% of chemotherapy drugs from the bloodstream, potentially reducing toxic side effects. The technology uses an absorbent polymer coating on a 3D-printed cylinder inserted into a vein, which sops up excess drugs before they reach other organs.
Scientists have created a 3D-printed device that can absorb excess chemotherapy drugs from a patient's bloodstream before they spread to healthy cells. The device captured about 64% of doxorubicin, a commonly used chemotherapy drug, reducing the likelihood of side effects such as hair loss and nausea.
A Dartmouth-led study reveals that exposure to sugary breakfast cereal advertising directly influences children's diets, leading to increased intake of those cereals. The research suggests a concerning link between child-directed high-sugar cereal TV advertising and brand-specific cereal consumption among preschoolers.
The Polsky Urologic Cancer Institute will provide personalized, integrated, and innovative care to individuals with urologic cancers through a disease-centric program of research, education, and discovery. The institute aims to transform how urologic cancers are treated in Chicago and worldwide.
Researchers have discovered a new way to boost the immune system's attack on cancer cells by blocking a routine cell mechanism. This breakthrough has shown promising results in lung and melanoma cancers, offering a potential solution for treating a large number of patients.
Researchers at MIT have developed an inhalable form of messenger RNA that can be delivered directly to the lungs, showing promise for treating various lung diseases. The aerosol-formulated mRNA was found to induce lung cells in mice to produce a target protein, paving the way for potential treatments.
The Mark Foundation has awarded grants to eight promising early career scientists pursuing innovative projects in cancer risk prediction, prevention, detection, and treatment. The recipients aim to tackle diverse areas of basic, translational, and early clinical cancer research.
A recent study has found that standard treatment for glioblastoma is more effective in women than men, with tumor growth velocity showing a steady decline after treatment. The researchers identified distinct molecular signatures of the disease in men and women, which could lead to sex-specific treatment strategies.
Recent advances in computational methods enhance the accuracy and reproducibility of label-free quantification (LFQ) in cancer proteomics, enabling discovery of anti-cancer targets and drugs. The study evaluates popular acquisition techniques and state-of-the-art quantification tools to improve LFQ performance.
A study using monkeys with the breast cancer drug letrozole found significant behavioral changes and impaired brain function, including hot flashes, increased anxiety, and spatial memory issues. The research highlights the importance of studying the effects of estrogen-reducing treatments on the nervous system.
Northwestern University scientists discovered two successful therapies that slowed pediatric leukemia progression in mice, according to recent studies. The research focused on stabilizing the MLL protein, which can slow cancer growth and increase survival rates.
Case Western Reserve University researcher Sanjay Gupta has been awarded nearly $1 million to investigate drug resistance mechanisms in prostate cancer. He will test two promising medications, simvastatin and metformin, to overcome drug resistance and halt metastasis.
A Columbia professor has developed a predictive computer platform that analyzes all tumor types and predicts effective treatment options. The platform, OncoTreat, is based on advanced data science techniques, including information theory and ray-tracing.
The review examines chemotherapeutic drugs that bind to plasma proteins, such as cisplatin, 5-fluorouracil, and ruthenium-based compounds. These drugs interact with key plasma protease inhibitors, altering their function and inactivating them.
Researchers discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, indicating a possible pathway for treatment. The approach has promise for patients who are or become resistant to immunotherapy drugs after a recurrence of their tumors.
Research identifies chain reaction in cells that helps cancer survive BRAF and MEK treatment. A new process called ER translocation connects two common resistance mechanisms, increasing autophagy and drug resistance.
A new study has found that long-term therapy with lenalidomide doubles remission duration and improves survival in younger patients by almost 8%. The treatment is also shown to prolong the average remission time by more than two years in younger patients.
Researchers identify DPYSL3 as a molecule whose expression is altered in Claudin-Low triple-negative breast cancer, a highly metastatic and aggressive subtype. The study suggests that targeting the connection between DPYSL3 and vimentin could lead to new treatments for this disease.
Researchers found that metformin and syrosingopine combination blocks critical energy production step, driving cancer cells to death. The duo targets NAD+ regeneration, preventing lactate export and leading to cell demise.
Researchers found that anti-PD-1 therapy induces CD8+ T cells to produce interferon-gamma, which activates dendritic cells to produce IL-12, a potent activating signal. This interaction improves the efficacy of anti-PD-1 therapies and offers potential ways to broaden their application.
A novel tool has been developed to identify genetic changes in Lynch syndrome genes associated with disease symptoms. The tool, combining laboratory test results with computer-based modeling and clinical data, achieves an accuracy of about 97 percent, making it suitable for clinical use.
David Cheresh, a renowned cancer researcher, has received a $4.2 million NCI award to investigate how tumors adapt to stress and develop drug resistance. His research aims to find ways to perturb the malignant cell version of wound repair, potentially eliminating highly drug-resistant cancers.
The study discovered fractal characteristics in gene expression, enabling the prediction of gene-to-gene interactions. This knowledge can help scientists engineer cells to perform specific tasks, such as drug delivery for cancer treatment.
A new EU Horizon 2020 project aims to produce therapeutic substances in baker's yeast, providing an eco-friendly alternative to traditional methods. Researchers will map the biosynthetic pathways of Indian snakeroot to create a sustainable production route.
A recent study presented at EuroEcho-Imaging 2018 suggests that breast cancer patients who take the beta-blocker carvedilol together with trastuzumab have better-preserved left ventricular function compared to those who take trastuzumab alone. This may indicate that carvedilol can help prevent heart damage caused by trastuzumab treatment.
A study by Baylor College of Medicine researchers found that when Dna2 is absent, small DNA fragments insert themselves into chromosome breaks, leading to genomic instability. This mechanism may contribute to cancer development and other cellular conditions.
A new study optimizes drug dose sizes available, reducing pharmaceutical wastage by as much as 50% in some cases. This can help cut drug manufacturer's costs and make medicines more accessible to patients.
Researchers at SWOG share findings from three studies on breast cancer subtypes, treatment response, and recurrence. The studies used existing trial data to identify subsets of patients and tumors with distinct characteristics, which can inform treatment decisions.
A new study identifies Frizzled 5 as a promising target for developing drugs against cancer, cardiovascular disease, and fibrosis. The receptor's activation in the cell membrane triggers specific processes within the cell, making it an attractive target for future drug development.
A new combined action drug was developed by Russian scientists using ionizing radiation and bacterial toxin, showing a 2,200 times stronger effect than separate use. The drug selectively targets tumor cells and facilitates visualization of tumors, making it a diagnostic tool for cancer treatment.
A study found that older adults with heart failure who take five or more medications are at higher risk for cognitive impairment and difficulty performing daily activities. The researchers suggest that healthcare providers should consider these limitations when prescribing medications, as they may unnecessarily expose patients to incre...
A new combination therapy involving ipilimumab, nivolumab, and brentuximab vedotin safely reduces tumor size or spread in 95% of patients with recurrent Hodgkin lymphoma, achieving complete remission in 16 patients.
A recent study found that around 72% of women at higher risk of breast cancer are worried about the long-term effects of tamoxifen, while 57% believe it will give them unpleasant side-effects. Despite its proven ability to prevent breast cancer, fewer than 15% of women with discussed preventive therapy are taking tamoxifen.
Researchers found that checkpoint blockade therapy can sensitize patients to better respond to future use of drugs, even when initial attempts failed. This breakthrough has significant implications for treating relapsing non-Hodgkin lymphoma and Hodgkin lymphoma patients.
A new immunotherapy called pembrolizumab has shown significant benefits in extending the lives of people with advanced head and neck cancer, with a median survival time of 8.4 months compared to 6.9 months on standard treatment. The drug also caused fewer serious side effects than traditional treatments.
Researchers found that vorinostat effectively inhibited HPV DNA amplification and virus production in preclinical experiments. Additionally, the treatment induced programmed cell death in infected cells. The study suggests that HDAC inhibitors could be promising compounds for treating benign HPV infections.
A randomized clinical trial found immunotherapy drug pembrolizumab more effective than standard chemotherapy in treating chemotherapy-resistant head and neck cancer. Patients receiving pembrolizumab had a higher response rate with longer-lasting responses compared to those on standard therapy.
A new combination of venetoclax with standard drugs azacitidine or decitabine has been granted accelerated approval for treating elderly patients with acute myeloid leukemia. The trial showed a 67% overall response rate, with improved efficacy and tolerability compared to traditional hypomethylating agents.
A study found that restricting cancer cells' ability to metabolize sugar makes oncolytic viruses work better, multiplying faster and destroying cancer quicker. This approach may improve how potential cancer drugs are investigated in the lab.
Seven researchers from the University of California, San Diego have been recognized as AAAS Fellows for their groundbreaking work in various fields. Robert Continetti was honored for his novel studies on molecular reaction dynamics, while Farhat Beg received recognition for his contributions to high energy density science.
The LION LBD AI system is designed to assist scientists in the search for cancer-related discoveries by analyzing tens of millions of publications. By identifying indirect associations between entities, it can help researchers make new connections and discover potential links that may have been overlooked.
Researchers have identified a genetic change common to 80% of human melanomas and developed a molecule that targets this change. The molecule binds to melanocortin-1 receptor (MC1R) on the surface of melanoma cells, allowing for imaging and potential therapy delivery.
Researchers have discovered a new way to target drug-resistant tumors by combining EGFR and Aurora Kinase A inhibitors. Elevated levels of TPX2 protein in biopsies can predict tumor susceptibility to combined therapies.
University of Michigan researchers have developed a new building block that can serve as a safer alternative for the development of new medicines. The novel compound is produced using visible light and does not produce harmful metabolites like traditional anilines.
A Chinese scientist designed a DNA origami nanoplatform that carries chemotherapeutic drugs and RNA interference to target and kill multidrug-resistant cancer cells. The platform demonstrates the effectiveness of RNA interference in reducing drug resistance in cancer treatment.